Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer

Chinese Journal of Cancer Research

Volumn 24, Issue 2, 2012, Pages 130-137

  Liu, Chan Zhen ^a   Zhang, Li ^a   Chang, Xiao Hong ^a   Cheng, Ye Xia ^a   Cheng, Hong Yan ^a   Ye, Xue ^a   Fu, Tian Yun ^a   Chen, Jun ^a   Cui, Heng ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Cytokines; Epithelial ovarian cancer; Immunosuppression; Tumor microenvironment

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; BIOACCUMULATION; CANCER PATIENT; CANCER TISSUE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84863671592     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-012-0130-y     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990; 63:245-7.
3. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24:99-146.
4. Kriegel MA, Li MO, Sanjabi S, et al. Transforming growth factor-beta: recent advances on its role in immune tolerance. Curr Rheumatol Rep 2006; 8:138-44. (Pubitemid 44623982)
5. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359:693-9.
6. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342:1350-8. (Pubitemid 30408720)
7. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-103. (Pubitemid 26338628)
8. Furlan D, Sahnane N, Carnevali I, et al. Up-regulation of the hypoxiainducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 2008; 39:1483-94.
9. Huang CL, Liu D, Ishikawa S, et al. Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 2008; 44: 2680-8.
10. Oh SY, Kwon HC, Kim SH, et al. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008; 8:123.
11. Kwon HC, Kim SH, Oh SY, et al. Clinicopathological significance of p53, hypoxia-inducible factor 1alpha, and vascular endothelial growth factor expression in colorectal cancer. Anticancer Res 2010; 30:4163-8.
12. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996; 74:1105-15. (Pubitemid 26184421)
13. Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000; 83:196-203. (Pubitemid 30411717)
14. Duncan TJ, Al-Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 2008; 14:3030-5.
15. Volk H, Asadullah K, Gallagher G, et al. IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets. Trends Immunol 2001; 22:414-7. (Pubitemid 32709967)
16. Wakkach A, Cottrez F, Groux H. Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw 2000; 11:153-60.
17. Nash MA, Lenzi R, Edwards CL, et al. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumourinfiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines. Clin Exp Immunol 1998; 112:172-80. (Pubitemid 28266674)
18. Rabinovich A, Medina L, Piura B, et al. Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 2010; 21:122-8.
19. Law AK, Lam KY, Lam FK, et al. Image analysis system for assessment of immunohistochemically stained proliferative marker (MIB-1) in oesophageal squamous cell carcinoma. Comput Methods Programs Biomed 2003; 70:37-45. (Pubitemid 35447527)
20. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11:8326-31. (Pubitemid 41746944)
21. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13. (Pubitemid 36077915)
22. Gordinier ME, Zhang HZ, Patenia R, et al. Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma. Clin Cancer Res 1999; 5:2498-505. (Pubitemid 29437334)
23. Shi HR, Song WJ, Chen ZM, et al. Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma. Ai Zheng 2005; 24:1127-31.
24. Diaz-Valdes N, Basagoiti M, Dotor J, et al. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 2011; 71:812-21.
25. Gholamin M, Moaven O, Memar B, et al. Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg 2009; 33:1439-45.
26. Troy A, Davidson P, Atkinson C, et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol 1998; 160:214-9. (Pubitemid 29479465)
27. Troy AJ, Summers KL, Davidson PJ, et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998; 4:585-93. (Pubitemid 28193556)
28. Pinzon-Charry A, Ho CS, Laherty R, et al. A population of HLA-DR+immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia 2005; 7:1112-22. (Pubitemid 44430990)
29. Bergeron A, El-Hage F, Kambouchner M, et al. Characterisation of dendritic cell subsets in lung cancer micro-environments. Eur Respir J 2006; 28:1170-7. (Pubitemid 44883852)
30. Baleeiro RB, Anselmo LB, Soares FA, et al. High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-alpha in lung cancer. Cancer Immunol Immunother 2008; 57:1335-45.
31. Kryczek I, Liu R, Wang G, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69:3995-4000.
32. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74. (Pubitemid 40488632)
33. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
34. Zhu X, Ma LL, Ye T. Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance. J Clin Lab Anal 2009; 23:197-201.
35. Zhou J, Ding T, Pan W, et al. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009; 125:1640-8.
36. Li L, Chao QG, Ping LZ, et al. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC. Cancer Biother Radiopharm 2009; 24:357-67.
37. Haas M, Dimmler A, Hohenberger W, et al. Stromal regulatory T-cells are associated with a favorable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009; 9:65.
38. Brinkrolf P, Landmeier S, Altvater B, et al. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 2009; 125:879-86.
39. Hinz S, Pagerols-Raluy L, Ober HH G, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007; 67:8344-50. (Pubitemid 47395173)
40. Li X, Ye DF, Xie X, et al. Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest 2005; 23:399-403. (Pubitemid 41324357)
41. Li X, Ye F, Chen H, et al. Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta. Cancer Lett 2007; 253:144-53. (Pubitemid 46874736)